Last reviewed · How we verify
Guselkumab (GUS)
Guselkumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
Guselkumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Crohn's disease.
At a glance
| Generic name | Guselkumab (GUS) |
|---|---|
| Also known as | TREMFYA, Tremfya |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | IL-23 inhibitor monoclonal antibody |
| Target | IL-23 (p19 subunit) |
| Modality | Small molecule |
| Therapeutic area | Immunology/Dermatology |
| Phase | FDA-approved |
Mechanism of action
Guselkumab binds to the p19 subunit of IL-23, a key cytokine involved in the differentiation and activation of pathogenic T helper 17 (Th17) cells. By blocking IL-23, the drug suppresses the inflammatory cascade that drives autoimmune and inflammatory skin diseases. This mechanism is distinct from TNF inhibitors and other biologics, offering an alternative pathway for treating IL-23-dependent inflammatory conditions.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
- Headache
Key clinical trials
- A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
- A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) (PHASE4)
- Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
- Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
- Real-Life Evaluation of Guselkumab Dosing Interval Adjustments
- VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study
- Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients (PHASE3)
- Multi-Center PAMPA Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: